Harmonization of Amoxicillin Dose, Duration, and Formulation for Acute Childhood Respiratory Infections

Area of Science:

• Pediatrics
• Infectious Diseases
• Pharmacology

Background:

• Pediatric guidelines present inconsistent amoxicillin dosing recommendations for common respiratory infections.
• Lack of harmonization complicates program delivery and antibiotic stewardship.
• Factors influencing optimal dosing include pharmacokinetics, common pathogens, antimicrobial resistance, cost, and administration ease.

Purpose of the Study:

• To advocate for harmonized amoxicillin dosing and formulation for pediatric respiratory infections.
• To align pediatric dosing with World Health Organization (WHO) EML AWaRe Book recommendations.
• To assess feasibility using WHO-recommended child formulations (dispersible tablets).

Main Methods:

• Review of current pediatric amoxicillin dosing guidelines for respiratory infections.
• Analysis of World Health Organization EML AWaRe Book recommendations for antibiotic use.
• Evaluation of amoxicillin dispersible tablet (DT) formulations (250 mg and 500 mg) for achieving WHO dosing.

Main Results:

• The WHO AWaRe Book suggests higher-dose amoxicillin, administered twice daily for five days, for uncomplicated respiratory infections.
• WHO-recommended amoxicillin dispersible tablets (250 mg and 500 mg) can effectively deliver the recommended dosing regimen for both infants and older children.
• Current availability of these specific dispersible tablet strengths may be limited in public and private healthcare sectors.

Conclusions:

• Harmonized amoxicillin dosing, following WHO guidelines, is achievable using 250 mg and 500 mg dispersible tablets.
• Increased availability of WHO-recommended amoxicillin dispersible tablets is essential for improving access to essential antibiotics in pediatric care.
• Standardizing amoxicillin formulation and dosing can enhance treatment efficacy and combat antimicrobial resistance.